Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Payoneer Global Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Payoneer Global Inc trades at $7.11 (market cap $2.40B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.3× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | PAYO | |
|---|---|---|
Market Cap | $8.02B | $2.40B |
Sector | Health | Technology |
52-Week High | $339.75 | $7.42 |
52-Week Low | $241.71 | $4.27 |
Enterprise Value | $7.84B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Payoneer (PAYO) trades at $7.10, flat on the day, with a bullish technical signal driven by moving averages. The company reported Q1 2026 EPS of $0.06, beating expectations, but missed in Q3 and Q4 2025. Revenue grew to $821.16M in 2025, though net income fell to $73.19M. Analysts maintain a 60% buy rating with an $8.20 consensus target. Recent news highlights a $2.75B acquisition by Nuvei and expansion into India, boosting sentiment but raising fairness concerns.
Outlook is mixed: the Nuvei deal offers a near-term exit at $7.40, but growth initiatives like India expansion provide long-term potential. Risks include integration challenges, margin pressure, and shareholder litigation over acquisition terms. The stock's current price near the low target suggests limited upside unless the deal is renegotiated or standalone execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
